Physician, Former NFL Player Joins Neuvivo to Advance Effective ALS Treatments for PatientsPALO ALTO, Calif., Jan. 17, 2024 /PRNewswire/ -- Neuvivo, a private, late-clinical-stage biopharmaceutical company focused on creating and delivering advanced treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Dr.

医生，前NFL球员加入Neuviod，为患者推进有效的ALS治疗加利福尼亚州帕洛阿尔托，2024年1月17日/PRNewswire/--Neuviod是一家私营的临床晚期生物制药公司，专注于创建和提供肌萎缩侧索硬化症（ALS）和其他神经退行性疾病的先进治疗方法，今天宣布任命Dr。

James Kovach, MD, JD, as its new Chief Medical Affairs Officer..

詹姆斯·科瓦奇（JamesKovach），医学博士，法学博士，新任首席医务官。。

Continue Reading

继续阅读

Dr. James J. Kovach, Chief Medical Affairs Officer, Neuvivo

Neuvivo首席医务官James J.Kovach博士

Dr. Kovach, previously a member of the Neuvivo Advisory Board and the former Executive Director of the UC Davis Health Translational Entrepreneurship program and Chief Innovation Officer and Co-Founder of innovation center Aggie Square, brings to Neuvivo 30 years of unrivaled expertise in the advancement of novel technology and late-stage drug development, with a focus on neurodegenerative diseases..

科瓦奇博士曾任纽维梧咨询委员会成员、加州大学戴维斯分校健康转化创业计划前执行董事、首席创新官、创新中心阿吉广场联合创始人，为纽维梧带来了30年来在新技术进步和晚期药物开发方面无与伦比的专业知识，专注于神经退行性疾病。。

Ari Azhir, PhD, Founder and CEO of Neuvivo, commented, 'Dr. Kovach's appointment to our leadership team represents a significant milestone for Neuvivo. His distinguished career, clinical expertise, and biotechnology and biopharmaceutical experience with neurodegenerative diseases make him an invaluable asset as we move into a critical phase of development and innovation.' Azhir added, 'Jim has firsthand experience, as a physician and as a former professional football player who has advised the NFL on the disproportionate impact of ALS on former athletes.

Neuvivo创始人兼首席执行官AriAzhir博士评论道。科瓦奇被任命为我们的领导团队，这对纽维梧来说是一个重要的里程碑。他杰出的职业生涯、临床专业知识以及在神经退行性疾病方面的生物技术和生物制药经验，使他成为我们进入发展和创新关键阶段的宝贵财富。”阿齐尔补充道，“吉姆拥有第一手经验，他是一名医生，也是一名前职业足球运动员，曾就ALS对前运动员产生的不相称影响向NFL提供过咨询。

His experience fuels his passion and resolve - and ours.'.

他的经历激发了他的热情和决心，也激发了我们的热情和决心。”。

A former NFL linebacker for the New Orleans Saints and San Francisco 49ers, Dr. Kovach has served as a member of the NFL Head, Neck and Spine Committee and currently serves on the Scientific Advisory Boards of the National Football League Alumni Association and Harvard Football Players Study. He also has served previously as the President of the Buck Institute, an NIH designated Center of Excellence for Research on Aging.'I feel the breadth of my experiences have been a training set for this moment,' said Dr. Kovach, Chief Medical Affairs Officer, Neuvivo.

科瓦奇博士曾是新奥尔良圣徒队和旧金山49人队的NFL后卫，曾担任NFL头颈脊柱委员会成员，目前担任国家足球联盟校友会和哈佛足球运动员研究的科学顾问委员会成员。他还曾担任美国国立卫生研究院指定的衰老研究卓越中心巴克研究所（Buck Institute）的院长纽维梧首席医疗事务官科瓦奇博士说，我觉得我的经验广博，这是目前的一项训练。

'ALS has a vast, unmet need for treatments, including our military personnel and football players, who are four times more likely to develop the disease.  I couldn't be more honored or committed to advancing Neuvivo's mission to bring new, effective treatments to our community.'At Neuvivo, Dr. Kovach will lead key global functions related to the development and commercialization of Neuvivo's therapeutic pipeline, including medical affairs and the presentation and communication of clinical and scientific information about Neuvivo's lead drug candidate, NP001, to key stakeholders, including the medical community, patient groups, payers and others.This strategic announcement comes as the company prepares to present new clinical data regarding NP001 and valuable insights into ALS treatment advancements at the 14th Annual California ALS Research Summit on January 19, 2024.About NeuvivoNeuvivo is a private, late-clinical stage biopharmaceutical company dedicated to creating and delivering advanced treatments for ALS and other neurodegenerative diseases.

“ALS对治疗的需求巨大，尚未得到满足，包括我们的军事人员和足球运动员，他们患这种疾病的可能性是我们的四倍。我非常荣幸或致力于推进纽维梧的使命，为我们的社区带来新的有效治疗方法。”在纽维梧，科瓦奇博士将领导与纽维梧治疗渠道的开发和商业化相关的关键全球职能，包括医疗事务以及向关键利益相关者（包括医学界、患者群体、付款人和其他人）介绍和交流纽维梧主要候选药物NP001的临床和科学信息。该战略公告发布之际，该公司正准备在2024年1月19日举行的第14届加利福尼亚州ALS研究峰会上提供有关NP001的新临床数据以及对ALS治疗进展的宝贵见解。关于NeuvivoNeuvivo是一家私人公司，晚期临床阶段生物制药公司致力于创建和提供ALS和其他神经退行性疾病的先进治疗方法。

Neuvivo has developed a proprietary technology platform that includes a patented macrophage-targeting technology, NP001, and its manufacture.  NP001 is designed to address t.

Neuvivo开发了一个专有技术平台，其中包括获得专利的巨噬细胞靶向技术NP001及其制造。NP001旨在解决t。